Cholesterol lowering and the use of healthcare resources : Results of the Scandinavian Simvastatin Survival Study.
Background Advanccs in the treatment of cardiovascular disease have increased costs ; annual cardiovascular healthcare expenditure in the United States currently exceeds $100 billion.
Physicians and third-party payers need to assess the economic impact of treatments that reduce cardiovascular morbidity and mortality.
Methods and Results The Scandinavian Simvastatin Survival Study is a randomized, double-blind, placebo-controlled trial in which simvastatin reduced the risk of death by 30% (P=0003) over the median follow-up period of 5.4 years in patients with previous myocardial infarction or stable angina pectoris as a result of a 42% reduction in the risk of coronary deaths (P=00001).
In the present report, data prospectively collected from hospital admissions were analyzed to evaluate the impact of simvastatin on healthcare resource use and perform a cost-minimization analysis.
In the placebo group (n=2223), there were 1905 hospitalizations (average duration, 7.9 days) for acute cardiovascular events or coronary revascularization procedures among 937 patients, whereas in the simvastatin group (n=2221), there were 1403 such hospitalizations (average duration, 7.1 days) among 720 patients (all differences, P<. 0001).
The corresponding number of hospital days was 15 089 and 9951 in the two groups, respectively (34% reduction, P<. 0001).
In the United States, the resulting reduction in hospitalization costs over the 5.4 years of the trial would he $3872 per ...
Mots-clés Pascal : Athérosclérose, Cardiopathie coronaire, Cholestérolémie, Simvastatine, Economie santé, Hospitalisation, Analyse avantage coût, Pays Scandinaves, Europe, Traitement, Survie, Homme, Hypolipémiant, Appareil circulatoire pathologie, Vaisseau sanguin pathologie, Analyse biochimique, Chimiothérapie, Evaluation
Mots-clés Pascal anglais : Atherosclerosis, Coronary heart disease, Cholesterolemia, Health economy, Hospitalization, Cost benefit analysis, Scandinavia, Europe, Treatment, Survival, Human, Antilipemic agent, Cardiovascular disease, Vascular disease, Biochemical analysis, Chemotherapy, Evaluation
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0284246
Code Inist : 002B02N. Création : 199608.